Table 1.
Baseline Features and Biochemical Indicators of the patients Between SAE group and Non-SAE group.
| Parameters | All Patients | SAE group | No-SAE group | p values |
|---|---|---|---|---|
| (n = 104) | (n = 59) | (n = 45) | ||
| Age, years (mean ± SD) | 56 ± 14 | 54 ± 15 | 58 ± 14 | 0.164 |
| Gender, n (Male/Female) | 70/34 | 38/21 | 32/13 | 0.691 |
| APACHE II scores | 17(11–22) | 21(17–25) | 17(9–16) | <0.001 |
| Max SOFA scores | 9(6–13) | 11(9–14) | 5(4–9) | <0.001 |
| Shock, yes (%) | 55(55.77) | 44(74.58) | 11(24.44) | <0.001 |
| GCS scores | 14(12–15) | 13(12–13) | 15(15–15) | <0.001 |
| LOS ICU, days | 6(3–9) | 7(4–11) | 4(3–9) | 0.005 |
| 28-day mortality, n (%) | 32(31.77) | 27(45.76) | 5(11.11) | <0.001 |
| 180-day mortality, n (%) | 44(42.31) | 32(54.24) | 12(26.67) | 0.005 |
| Source of infection | ||||
| Lung | 14(13.46) | 11(18.64) | 3(6.67) | 0.076 |
| Abdominal cavity | 72(69.23) | 40(67.80) | 32(71.11) | 0.717 |
| Urinary tract | 14(13.46) | 7(11.86) | 7(15.56) | 0.863 |
| Others | 4(3.85) | 1(1.69) | 3(6.67) | 0.183 |
| Bacteriological categories | ||||
| Gram-negative bacteria | 53(50.96) | 36(61.12) | 17(37.78) | 0.019 |
| Gram-positive bacteria | 30(28.85) | 16(27.12) | 14(31.11) | 0.656 |
| Fungal | 13(12.50) | 9(15.25) | 4(8.89) | 0.331 |
| Mixed infection | 22(21.15) | 15(25.42) | 7(15.56) | 0.222 |
| Blood culture positive, n(%) | 23(22.12) | 13(22.03) | 10(22.22) | 0.982 |
| Number of comorbidities ≥1 | 48(46.15) | 27(45.76) | 21(46.67) | 0.927 |
| WBC ×109/L | 9.2(4.9–15.7) | 8.0(3.6–14.9) | 10.6(7.1–17.5) | 0.032 |
| PLT ×109/L | 100(50–172) | 94(42–149) | 115(70–213) | 0.034 |
| MPV, fl | 9.65(8.59–10.95) | 9.8(8.58–10.88) | 9.42(8.58–11.1) | 0.682 |
| S100B on day 1, μg/L | 0.217 (0.115–0.430) | 0.291 (0.174–0.478) | 0.157 (0.09–0.218) | <0.001 |
| S100B on day 3, μg/L | 0.140 (0.082–0.276) | 0.226 (0.129–0.447) | 0.089 (0.053–0.136) | <0.001 |
| Procalcitonin on day 1, ng/ml | 24.6(5.9–65.8) | 31.3(10.1–69.0) | 16.0(3.9–62.6) | 0.064 |
| Procalcitonin on day 3, ng/ml | 15.9(3.9–43.1) | 23.8(7.3–72.4) | 7.52.4–32.6) | 0.001 |
| Serum Lactate on day 1, mmol/L | 2.35(1.23–3.58) | 2.9(2.0–4.5) | 1.5(1.0–2.5) | <0.001 |
| Serum Lactate on day 3, mmol/L | 1.15(0.90–2.08) | 1.7(1.0–2.4) | 0.9(0.6–1.1) | <0.001 |
| Creatinine on day 1, µmol/L | 127.7 (87.1–206.5) | 137.0 (102.1–210.7) | 105.5 (77.7–213.2) | 0.042 |
| Creatinine on day 3, µmol/L | 98.3 (72.1–145.4) | 107.9 (80.9–146.2) | 78.7 (66.6–146.0) | 0.056 |
| PH on day 1 | 7.34 ± 0.11 | 7.33 ± 0.12 | 7.35 ± 0.09 | 0.368 |
| PH on day 3 | 7.42 ± 0.07 | 7.41 ± 0.07 | 7.42 ± 0.06 | 0.473 |
| PaO2/FiO2 on day 1 | 262 ± 134 | 235 ± 133 | 297 ± 129 | 0.019 |
| PaO2/FiO2 on day 3 | 262 ± 98 | 239 ± 97 | 291 ± 92 | 0.007 |
| Interleukin-6 on day 1, pg/L | 226.2 (82.5–1385.8) | 534.7 (93.3–5000) | 138.2 (68.1–387.3) | 0.001 |
| Interleukin-6 on day 3, pg/L | 129.5 (50.6–338.7) | 220.6 (83.6–1002.0) | 59.6 (41.3–165.4) | <0.001 |
APACHE, Acute Physiology and Chronic Health Evaluation score; Max SOFA score, maximum Sequential Organ Failure Assessment score evaluated at the fourth day of inclusion; GCS, Glasgow Coma Scale; ICU, intensive care unit; LOS, length of stay; MPV, mean platelet volume. Results are expressed as mean ± SD or median (interquartile range), chi-square test, independent two-samples t-test and Mann-Whitney U test were used for comparison between SAE group and No-SAE group.